Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial.

MLA

Koshino, Akihiko, et al. “Effects of Canagliflozin on Liver Steatosis and Fibrosis Markers in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Post Hoc Analysis of the CREDENCE Trial.” Diabetes, Obesity & Metabolism, vol. 25, no. 5, May 2023, pp. 1413–18. EBSCOhost, https://doi.org/10.1111/dom.14978.

APA

Koshino, A., Oshima, M., Arnott, C., Fletcher, R. A., Bakris, G. L., Jardine, M., Mahaffey, K. W., Perkovic, V., Pollock, C., Heerspink, H. J. L., & Neuen, B. L. (2023). Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial. Diabetes, Obesity & Metabolism, 25(5), 1413–1418. https://doi.org/10.1111/dom.14978

Chicago

Koshino, Akihiko, Megumi Oshima, Clare Arnott, Robert A Fletcher, George L Bakris, Meg Jardine, Kenneth W Mahaffey, et al. 2023. “Effects of Canagliflozin on Liver Steatosis and Fibrosis Markers in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Post Hoc Analysis of the CREDENCE Trial.” Diabetes, Obesity & Metabolism 25 (5): 1413–18. doi:10.1111/dom.14978.